Sugi Predict

Sugi Predict / Compounds / SCHEMBL19953369

SCHEMBL19953369

SCHEMBL19953369

COc1ccc(Cn2ncc3c(O)cc(C)nc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE1A P54750 5/20 0.50
▸ PDE1B Q01064 5/20 0.50
▸ PDE1C Q14123 5/20 0.50
▸ ALDH1A1 P00352 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CNR2 P34972 3/20 0.47
▸ PKM P14618 1/20 0.44
▸ PKLR P30613 1/20 0.44
▸ NPBWR1 P48145 6/20 0.44
▸ HPGD P15428 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MCHR1 Q99705 1/20 0.44
▸ HSD17B3 P37058 1/20 0.42
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16014436 0.89 PDE1A (0.51) PDE1APDE1BPDE1CALDH1A1LMNA
SCHEMBL29514413 0.85 PDE1B (0.50) PDE1APDE1BPDE1CALDH1A1LMNA
SCHEMBL29049927 0.85 PDE1B (0.50) PDE1APDE1BPDE1CALDH1A1LMNA
SCHEMBL1695446 0.84 ALDH1A1 (0.50) ALDH1A1LMNAMAPTSMN1; SMN2PKM
SCHEMBL1944851 0.80 LMNA (0.53) PDE1APDE1BPDE1CALDH1A1LMNA
SCHEMBL21796811 0.79 NPBWR1 (0.46) PDE1APDE1BPDE1CALDH1A1LMNA
SCHEMBL24044245 0.78 PDE1A (0.44) PDE1APDE1BPDE1CALDH1A1LMNA
SCHEMBL29514251 0.78 UCHL1 (0.57) PDE1APDE1BPDE1CALDH1A1LMNA
SCHEMBL26720579 0.78 UCHL1 (0.57) PDE1APDE1BPDE1CALDH1A1LMNA
SCHEMBL29050032 0.78 LMNA (0.42) ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615847-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS Merck Sharp & Dohme LLC (US) 2025-09-17 — — EP disclosed
US-20240376099-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2024-11-14 — — US disclosed
CN-115215886-B Compounds and compositions as endosomal Toll-like receptor inhibitors 诺华股份有限公司 2024-10-11 — — CN disclosed
WO-2024103010-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS MERCK SHARP & DOHME LLC (US) 2024-05-16 — — WO disclosed
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 — — US disclosed
EP-4214199-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-07-26 — — EP disclosed
EP-4214214-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-07-26 — — EP disclosed
CN-116490503-A Casein kinase 1 delta modulators 詹森药业有限公司 2023-07-25 — — CN disclosed
CN-116171280-A Casein kinase 1 delta modulators 詹森药业有限公司 2023-05-26 — — CN disclosed
EP-4059934-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS Novartis AG (CH) 2022-09-21 — — EP disclosed
WO-2022058920-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 — — WO disclosed
EP-3510033-B1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2021-11-24 — — EP disclosed
US-20210101902-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2021-04-08 — — US disclosed
US-20210101902-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2021-04-08 — — US disclosed
US-10954233-B2 Compounds and compositions as inhibitors of endosomal toll-like receptors NOVARTIS AG (CH) 2021-03-23 — — US disclosed
EP-3510033-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS Novartis AG (CH) 2019-07-17 — — EP disclosed
US-20190211009-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. 2019-07-11 — — US disclosed
WO-2018047081-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2018-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376099-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS TLR3, TLR1, TLR4 PDE1A 3385/4885PDE1B 3105/4885PDE1C 3061/4885
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS CSNK1D, CSNK1A1, CSNK1G1 PDE1A 549/4885PDE1B 654/4885PDE1C 994/4885
US-20210101902-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS TLR3, TLR1, TLR4 PDE1A 3385/4885PDE1B 3105/4885PDE1C 3061/4885
US-20190211009-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS TLR3, TLR1, TLR4 PDE1A 3385/4885PDE1B 3105/4885PDE1C 3061/4885
US-10954233-B2 Compounds and compositions as inhibitors of endosomal toll-like receptors TLR3, TLR1, TLR4 PDE1A 3385/4885PDE1B 3105/4885PDE1C 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.